Li Yan

US Patent:

8477685, Jul 2, 2013

Filed:

Jul 30, 2009

Appl. No.:

12/512594

Inventors:

Li Yan - Holmdel NJ, US

Assignee:

Avaya, Inc. - Basking Ridge NJ

International Classification:

H04W 4/00
H04W 36/00
H04J 3/06
H04L 12/56

US Classification:

370328, 370349, 370352, 370401, 709245, 4554351, 455436

Abstract:

A method is disclosed that enables the transmission of media and signaling packets in a Proxy Mobile Internet Protocol-based (PMIP-based) network. A mobile access gateway is enhanced to differentiate between different types of packet traffic and to act as a Session Initiation Protocol (SIP) proxy on behalf of a mobile node. For example, the gateway is able to handle quality-of-service-sensitive (QoS-sensitive) traffic such as voice or video media packets differently from QoS-insensitive traffic such as SIP signaling packets. In the case of traffic packets that are not QoS-sensitive, the gateway engages standard PMIPv6 procedure. In the case of traffic packets that are in fact QoS-sensitive, the gateway acts as a SIP proxy for each mobile node attached to it, thereby avoiding tunneling of the packets between the gateway and the mobile node's local mobility anchor, and thereby reducing the amount of delay that affects the packets.

US Patent:

8618264, Dec 31, 2013

Filed:

Aug 19, 2009

Appl. No.:

13/062702

Inventors:

Mark Cunningham - Radnor PA, US
Yi Tang - Radnor PA, US
Li Yan - Berwyn PA, US

Assignee:

Centocor Ortho Biotech Inc. - Horsham PA

International Classification:

C07K 16/30

US Classification:

5303888, 5303873, 5303881

Abstract:

The present invention provides antibodies immunospecific for human CD147 capable of blocking bioactivity of CD147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system.

US Patent:

20050008638, Jan 13, 2005

Filed:

Jun 25, 2003

Appl. No.:

10/603313

Inventors:

Jin Lu - Boothwyn PA, US
Li Yan - Wayne PA, US
Chris Huang - Paoli PA, US
Marian Nakada - Malvern PA, US

International Classification:

C12Q001/68
C07H021/04
A61K039/395
C12N009/00
C07K016/40
C12P021/02
C12N005/06

US Classification:

424145100, 435006000, 536023200, 435069100, 435183000, 435320100, 435325000, 530388260

Abstract:

The present invention relates to at least one novel CNGH0005 polypeptides, antibodies, including isolated nucleic acids that encode at least one CNGH0005 polypeptide or antibody, CNGH0005 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

US Patent:

20050136451, Jun 23, 2005

Filed:

Oct 1, 2004

Appl. No.:

10/957503

Inventors:

Li Yan - Wayne PA, US
Chris Huang - Paoli PA, US
Prabakaran Kesavan - Blackwood NJ, US
Katherine Li - Wallingford PA, US
Marian Nakada - Malvern PA, US

International Classification:

C12Q001/68
C07H021/04
C12N009/02

US Classification:

435006000, 435069100, 435189000, 435320100, 435325000, 530350000, 536023200

Abstract:

The invention provides isolated nucleic acids encoding a variety of nucleic acids and proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acids molecules, expression vectors containing the nucleic acids molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acids molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

US Patent:

20050214302, Sep 29, 2005

Filed:

Mar 25, 2004

Appl. No.:

10/808699

Inventors:

Marian Nakada - Malvern PA, US
Li Yan - Berwyn PA, US
Yi Tang - Drexel Hill PA, US

International Classification:

A61K039/395

US Classification:

424155100

Abstract:

A method of using EMMPRIN antagonists to treat pathological processes associated with proliferative diseases, such as cancer, by specifically preventing or inhibiting the ability of new tissue to develop a blood supply. The invention more specifically relates to methods of treating such diseases by the use of EMMPRIN antagonists such as antibodies directed toward EMMPRIN, including specified portions or variants, specific for at least one EMMPRIN protein or fragment thereof, in an amount effective to inhibit angiogenesis.

US Patent:

20050232923, Oct 20, 2005

Filed:

Nov 5, 2004

Appl. No.:

10/981936

Inventors:

Li Yan - Berwyn PA, US
Marian Nakada - Malvern PA, US
Anuk Das - Wayne PA, US

International Classification:

A61K039/395
A61K038/18
A61K038/54
A61K031/137
A61K031/473
A61K031/445
A61K031/573

US Classification:

424146100, 514012000, 514169000, 514297000, 514319000, 514649000

Abstract:

The present invention relates to methods for treating at least one MCP-1 related condition or pathology, including therapeutic compositions, methods and devices.

US Patent:

20090028862, Jan 29, 2009

Filed:

Sep 29, 2005

Appl. No.:

11/664150

Inventors:

Gregory M. Arndt - New South Wales, AU
Mehnaaz Lomas - New South Wales, AU
Marian T. Nakada - Malvern PA, US
Laurent P. Rivory - New South Wales, AU
Yi Tang - Drexel Hill PA, US
Li Yan - Berwyn PA, US

International Classification:

A61K 39/395
A61K 31/7105
A61K 31/711
A61K 48/00
A61P 35/00

US Classification:

4241381, 514 44

Abstract:

EMMPRIN (Extracellular Matrix Metalloproteinase Inducer) antagonists, such as antibodies, including specified portions or variants, siRNA, shRNA, antisense and DNAzymes, can be used to treat pathological processes associated with proliferative diseases, such as cancer, by specifically preventing or inhibiting the ability of proliferating tissue to develop a blood supply.

US Patent:

20130270489, Oct 17, 2013

Filed:

Apr 17, 2013

Appl. No.:

13/864499

Inventors:

Heraeus Precious Metals North America Conshohocken LLC - , US
Li Yan - West Conshohocken PA, US
Cuiwen Guo - Horsham PA, US
Weiming Zhang - Blue Bell PA, US

Assignee:

Heraeus Precious Metals North America Conshohocken LLC - West Conshohocken PA

International Classification:

H01L 31/0264

US Classification:

252514

Abstract:

The invention provides an inorganic reaction system for the preparation of electroconductive paste. Particularly, an inorganic reaction system comprises conductive glass. The inorganic reaction system may comprise a silver containing matrix forming composition. The silver containing matrix composition may comprise at least one of silver oxide or silver halide, or both. The invention also provides solar cells manufactured utilizing an electroconductive paste comprising an inorganic reaction system comprising conductive glass, and methods of manufacturing solar cells utilizing an electroconductive paste comprising an inorganic reaction system comprising conductive glass.